In this study, we used ST for the tumor-targeted delivery of asRNA against RCAS1, evaluated the asRCAS1 suppression of RCAS1 in the tumor, and assessed the effect of the treatment on tumor growth, metastasis, tumor-associated macrophages, pro-oncogenic gene expression, and the T cell population level in tumor-bearing mice. The gene discussed is EBAG9; the disease is neoplasm.